<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">H. Verbeke</style></author><author><style face="normal" font="default" size="100%">Struyf,S.</style></author><author><style face="normal" font="default" size="100%">Berghmans,N.</style></author><author><style face="normal" font="default" size="100%">E. Van Coillie</style></author><author><style face="normal" font="default" size="100%">Opdenakker,G.</style></author><author><style face="normal" font="default" size="100%">Uyttenhove,C.</style></author><author><style face="normal" font="default" size="100%">J. Van Snick</style></author><author><style face="normal" font="default" size="100%">J. Van Damme</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Isotypic neutralizing antibodies against mouse GCP-2/CXCL6 inhibit melanoma growth and metastasis</style></title><secondary-title><style face="normal" font="default" size="100%">Cancer Lett.</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">)Melanoma</style></keyword><keyword><style  face="normal" font="default" size="100%">chemokine</style></keyword><keyword><style  face="normal" font="default" size="100%">Granulocyte chemotactic protein-2 (GCP-2</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2011</style></year><pub-dates><date><style  face="normal" font="default" size="100%">1/3/2011</style></date></pub-dates></dates><number><style face="normal" font="default" size="100%">62</style></number><volume><style face="normal" font="default" size="100%">302</style></volume><pages><style face="normal" font="default" size="100%">54 - 62</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;The chemokine granulocyte chemotactic protein (GCP)-2/CXCL6 promotes tumor growth as angiogenesis inducer and neutrophil chemoattractant. The neutralizing capacity and specificity of monoclonal mouse anti-murine (mu)GCP-2/CXCL6 antibodies were evidenced by granulocyte chemotaxis and signaling assays. The half-life of the non-antigenic antibody in the blood circulation was approximately 15 days. The titers remained constant upon weekly injection. Tumor growth and lymphogenic metastases of human melanoma over-expressing muGCP-2 were reduced in mice treated with anti-muGCP-2. Moreover, the drop in muGCP-2 antibody titer correlated with the melanoma tumor size. Taken together, we show that functional blocking of GCP-2 inhibits tumor growth and metastases&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">1</style></issue><custom1><style face="normal" font="default" size="100%">39045</style></custom1><section><style face="normal" font="default" size="100%">54</style></section></record></records></xml>